Daiichi Sankyo, AstraZeneca's $5B Enhertu follow-up shows early signs of success in breast cancer Abingworth raises $582M clinical co-development fund amid rising biotech interest KRAS biotech Mirati delivers so-so news for investors closely watching Amgen battle Centessa's new chief medical officer has AstraZeneca's Tagrisso, Lynparza on his resume Drug licenser LianBio poaches Lilly's COVID-19 antibody leader to fill CEO role Bayer's near-approval Farxiga rival meets goal in 2nd phase 3 Flagship debuts Laronde to develop RNA-based meds that could turn cells into protein factories BioNTech, Fosun Pharma eye 1B doses of COVID-19 vaccine capacity with new China JV Featured Story | By Ben Adams Daiichi Sankyo and partner AstraZeneca’s next-gen antibody-drug conjugate datopotamab deruxtecan has show glimmers of efficacy and a reasonable safety profile in its first data release in breast cancer. read more |
| |
|---|
|
Top Stories By Nick Paul Taylor Abingworth has raised $582 million for its second clinical co-development fund. The fund, ACCD 2, equips Abingworth to make triple-digit million investments in late-stage clinical programs. read more By Annalee Armstrong Mirati Therapeutics investors waiting to hear the latest in the KRAS inhibitor story were disappointed Thursday evening, as the biotech reported that a few key clinical developments have slipped into 2022. read more By Annalee Armstrong The resume of Antoine Yver, M.D., includes several of AstraZeneca’s most well-known approved cancer drugs including Tagrisso. He will now bring that expertise to Centessa Pharmaceuticals as chief medical officer. read more By Amirah Al Idrus As LianBio strikes more deals to bring new drugs to China, the company is installing a new CEO: Yizhe Wang, Ph.D., who will arrive next Monday after leading the team that brought Eli Lilly’s COVID-19 antibody, bamlanivimab, to an emergency nod. Wang fills a vacuum left by LianBio’s founding CEO Bing Li, who departed quietly earlier this year. read more By Nick Paul Taylor Bayer’s finerenone has met the primary endpoint in another phase 3 clinical trial. The study, which linked the mineralocorticoid receptor antagonist to a significant reduction over placebo against a composite cardiovascular event endpoint, has met the primary endpoint in another phase 3 clinical trial. read more By Amirah Al Idrus Antibodies and other protein therapeutics can treat a wide range of diseases, but they come with various challenges that have limited their reach. Laronde is using an RNA-based approach that could surmount these hurdles and yield medicines that give patients the ability to express therapeutic proteins in their own body instead of passively receiving those proteins through an injection. read more By Angus Liu As BioNTech makes inroads with its COVID-19 vaccine in Western countries under a partnership with Pfizer, the German biotech is bringing its work in China to the next level with a joint venture with licensing partner Fosun Pharma. The goal is to have manufacturing capacity of up to 1 billion doses a year. read more Resources Sponsored By: Veeva One top 10 pharma outlines three key steps to launching a modular content strategy to generate localized content faster. Sponsored By: Blue Matter This 77-page e-book explores 7 keys to success that any biopharma company needs to keep in mind as it enters Europe. Sponsored by: Datacubed Health The average clinical trial spends $40,000 per patient. Yet despite these high costs, most trials struggle to retain patients. Sponsored By: AmerisourceBergen Developing a quality product and getting it approved for distribution is not enough to guarantee commercial success. Sponsored By: WCG Trifecta The new standards in study training help sponsors and CROs reduce costs by 60%, cut training time by 50%, and start enrollment 55 days faster – learn more today. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process intesification Sponsored By: August Bioservices How has COVID-19 impacted CRO/CDMO customer (dis)satisfaction and outsourcing decisions for pharma and biotech companies in 2021 and beyond? Sponsored by: Cytiva A one-stop hub for Cytiva resources to support process development and manufacturing of your novel molecule Sponsored by: TAC Roche has inked a $1.8 billion, all-cash deal for GenMark Diagnostics, to acquire its molecular tests designed to screen patient samples for multiple infections simultaneously. Sponsored By: Remarque Systems Remarque Systems consolidates data, then layers on visualization and automated metrics to generate consistent, actionable data insights in real-time. Click here for more info. Sponsored By: Culture Biosciences Find out how upstream bioprocess scientists can use Culture Biosciences’ bioreactor system and real-time data visualizations to get faster insights and get their product to market more quickly. Sponsored By: BC Platforms Those wishing to unlock RWD’s true value must have access to a variety of data sources/types and the technological capabilities to use the data to uncover meaningful insights. Sponsored By: Oracle Health Sciences New research indicates an accelerated adoption of decentralized clinical trials due to COVID-19. Sponsored by: Catalent Autologous cell therapies have seen propelled growth since 2017, with the spotlight on the first FDA approval of a chimeric antigen receptor (CAR) T cell immunotherapy, Kymriah® (tisagenlecleucel), for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Sponsored by: Catalent Learn about drug product process development challenges and risks, the difference between innovator and biosimilar drug product process development, and more during the drug product process development phase. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Drug Development Boot Camp® 2021 Onsite and VIRTUAL in real time November 17-18, 2021 | Register now! Pre-Boot Camp preparation is now available. TMF Virtual Summit May 18-20, 2021 | Virtual Event Vaccines, cell and gene therapy, therapeutic antibodies and RNA drugs May 20-21, 2021 | 12 p.m. EST / 9 a.m. PST Vaccines, cell and gene therapy, antibodies, and RNA-based drugs June 10-11, 2021 | 9 a.m. EST / 6 a.m. PST Next Gen: What’s beyond the leading edge of biotech and pharma? June 22-23, 2021 | Virtual Event Biopharma Supply Chain June 29-30, 2021 | Virtual Event | 